For the first time, infants younger than 28 days (neonates) can safely receive Dolutegravir (DTG), one of the most effective and widely used HIV drugs worldwide.
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
CAGAYAN DE ORO CITY (PIA) — The Philippine Health Insurance Corporation (PhilHealth) reaffirmed its commitment to supporting ...
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...
Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...
Interesting Engineering on MSN4d
Revolutionary HIV injection could offer a full year of protection in just one doseA groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback